MacroGenics Inc (MGNX) stock
MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.20−0.09 (-3.93%)
Close on Nov 13, 2026Market cap $140.14MP/E –Yield –
MacroGenics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
MacroGenics's EPS for the twelve months ending Sep 30, 2026 was -$0.81. For fiscal 2025 it was -$1.18. The highest annual figure on record is $0.00 in fiscal 2011.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.18 | – |
| FY2024 | Dec 31, 2024 | -$1.07 | – |
| FY2023 | Dec 31, 2023 | -$0.15 | – |
| FY2022 | Dec 31, 2022 | -$1.95 | – |
| FY2021 | Dec 31, 2021 | -$3.37 | – |
| FY2020 | Dec 31, 2020 | -$2.47 | – |
| FY2017 | Dec 31, 2017 | -$0.54 | – |
| FY2016 | Dec 31, 2016 | -$1.69 | – |
| FY2015 | Dec 31, 2015 | -$0.63 | – |
| FY2014 | Dec 31, 2014 | -$1.40 | – |
| FY2013 | Dec 31, 2013 | -$0.04 | – |
| FY2012 | Dec 31, 2012 | $0.00 | – |
| FY2011 | Dec 31, 2011 | $0.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.32 | -218.5% |
| Q2 FY2026 | Jun 30, 2026 | $0.31 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.58 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.22 | – |
| Q3 FY2025 | Sep 30, 2025 | $0.27 | -70.0% |
| Q2 FY2025 | Jun 30, 2025 | -$0.57 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.65 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.25 | – |
| Q3 FY2024 | Sep 30, 2024 | $0.90 | +221.4% |
| Q2 FY2024 | Jun 30, 2024 | -$0.89 | -196.7% |
| Q1 FY2024 | Mar 31, 2024 | -$0.84 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.75 | -457.1% |
| Q3 FY2023 | Sep 30, 2023 | $0.28 | – |
| Q2 FY2023 | Jun 30, 2023 | $0.92 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.61 | – |
| Q4 FY2022 | Dec 31, 2022 | $0.21 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.40 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.67 | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.08 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.95 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.86 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.66 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.90 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.04 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.66 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.94 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.91 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.62 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.91 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.65 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.99 | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.06 | -137.9% |
| Q3 FY2018 | Sep 30, 2018 | -$0.81 | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.03 | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.34 | – |
| Q4 FY2017 | Dec 31, 2017 | $2.80 | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.28 | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.14 | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.08 | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?